Dr Springer on pharmacological response of RTX in ANCA-vasculitis. Suggest that 500mg every 6 months may not achieve sufficient B cell depletion in all. What are the clinical implications? Is anyone dosing 500mg as standard? Abstr#0416 #ACR21 @RheumNow https://t.co/w36hSYbW1B

In ANCA-associated vasculitis, does reverse seroconverting (ANCA+➡️ANCA-) make a difference? relapse - no ESRD - no death - no Don't measure serial ANCAs for prognosis (no diff MPO/PR3, RTX/CYC) target trial emulation @BrighamWomens @MGHrheumatology #ACR21 ABST0419 @RheumNow https://t.co/rLkTY0ul8f

ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparing therapy. Non-inferior outcome of remission, sustained remission, relapse wo signif adverse effects. @rheumnow #ACR21 https://t.co/m5zexRpeS8

#ACR21 #YearinReview Avacopan: The game changer for ANCA #vasculitis?🧐 🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001) 🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001) @RheumNow https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu

• https://bit.ly/2ZNHhAi

Dr. K Costenbader #ACR21 #YearinReview add-ons Rx: 👉Avacopan for AAV: new oral C5a inh allowed for remission & prevention of relapse, aggressive pred taper https://t.co/39V3LLOYKZ